JPWO2020260252A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020260252A5 JPWO2020260252A5 JP2021576576A JP2021576576A JPWO2020260252A5 JP WO2020260252 A5 JPWO2020260252 A5 JP WO2020260252A5 JP 2021576576 A JP2021576576 A JP 2021576576A JP 2021576576 A JP2021576576 A JP 2021576576A JP WO2020260252 A5 JPWO2020260252 A5 JP WO2020260252A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- alkylene
- linear
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181952.3 | 2019-06-24 | ||
| EP19181952 | 2019-06-24 | ||
| PCT/EP2020/067451 WO2020260252A1 (en) | 2019-06-24 | 2020-06-23 | New macrocyclic compounds and derivatives as egfr inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538228A JP2022538228A (ja) | 2022-09-01 |
| JPWO2020260252A5 true JPWO2020260252A5 (th) | 2023-06-26 |
Family
ID=67003267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576576A Pending JP2022538228A (ja) | 2019-06-24 | 2020-06-23 | Ｅｇｆｒ阻害剤としての新たな大環状化合物および誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220380382A1 (th) |
| EP (1) | EP3986564A1 (th) |
| JP (1) | JP2022538228A (th) |
| CN (1) | CN114007698B (th) |
| WO (1) | WO2020260252A1 (th) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113880804A (zh) * | 2020-07-01 | 2022-01-04 | 微境生物医药科技(上海)有限公司 | 新型苯并咪唑化合物 |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022117051A1 (zh) * | 2020-12-03 | 2022-06-09 | 北京鞍石生物科技有限责任公司 | 大环化合物及其制备方法和应用 |
| WO2022135432A1 (zh) * | 2020-12-23 | 2022-06-30 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
| CN116761603A (zh) * | 2021-02-06 | 2023-09-15 | 正大天晴药业集团股份有限公司 | 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途 |
| EP4301360A1 (en) * | 2021-03-02 | 2024-01-10 | Dana Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
| WO2022204544A1 (en) * | 2021-03-26 | 2022-09-29 | Theseus Pharmaceuticals, Inc. | Macrocyclic egfr inhibitors for the treatment of cancer |
| WO2022242712A1 (zh) * | 2021-05-21 | 2022-11-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的大环化合物及包含该化合物的组合物及其用途 |
| KR20240027696A (ko) * | 2021-06-30 | 2024-03-04 | 아킬리온 에이비 | 마크로사이클릭 tak1 억제제 |
| CN117794938A (zh) * | 2021-07-23 | 2024-03-29 | 南京明德新药研发有限公司 | 大环酰胺类化合物及其应用 |
| TW202330550A (zh) * | 2021-11-30 | 2023-08-01 | 大陸商正大天晴藥業集團股份有限公司 | 含有環烷基或鹵代烷基的化合物 |
| WO2023205595A2 (en) * | 2022-04-20 | 2023-10-26 | Celyn Therapeutics, Inc | Egfr inhibitors in cancer treatment |
| CN117024443A (zh) * | 2022-05-09 | 2023-11-10 | 元启(苏州)生物制药有限公司 | Egfr抑制剂及其用途 |
| WO2024016986A1 (zh) * | 2022-07-21 | 2024-01-25 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| WO2024017358A1 (zh) * | 2022-07-21 | 2024-01-25 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| WO2024046221A1 (en) * | 2022-09-02 | 2024-03-07 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Egfr inhibitors and uses thereof |
| WO2024078263A1 (zh) * | 2022-10-09 | 2024-04-18 | 药雅科技(上海)有限公司 | 大环杂环类化合物作为egfr抑制剂的制备及其应用 |
| WO2024099400A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| WO2024099402A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| WO2024099395A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene, Ltd. | Compounds for the degradation of egfr kinase |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1434579B1 (en) | 2001-10-09 | 2011-06-08 | Amgen Inc. | Imidazole derivatives as antiinflammatory agents |
| NZ533310A (en) | 2001-11-09 | 2004-12-24 | Boehringer Ingelheim Pharma | Benzimidazoles useful as protein kinase inhibitors |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7138420B2 (en) | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| WO2005079791A1 (en) | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| WO2007133983A2 (en) | 2006-05-08 | 2007-11-22 | Pharmacopeia, Inc. | 2-aminobenzimidazoles for treating neurodegenerative diseases |
| BR112013002879A2 (pt) | 2010-08-05 | 2016-05-31 | Amgen Inc | compostos de benizmidazol e azabenzimidazol que inibem a quinase de linfoma anaplásico |
| CN103159742B (zh) * | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| JO3300B1 (ar) * | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| EP2861578A1 (en) | 2012-06-06 | 2015-04-22 | Irm Llc | Compounds and compositions for modulating egfr activity |
| WO2014036016A1 (en) | 2012-08-31 | 2014-03-06 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| JP6267729B2 (ja) * | 2013-02-07 | 2018-01-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 大環状ピリダジノン誘導体 |
| EP3052494B1 (en) | 2013-06-28 | 2018-12-26 | H. Hoffnabb-La Roche Ag | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| AU2015231215B2 (en) | 2014-03-20 | 2019-07-18 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
| KR102663309B1 (ko) | 2014-03-20 | 2024-05-03 | 카펠라 테라퓨틱스, 인크. | 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체 |
| WO2016176473A1 (en) | 2015-04-28 | 2016-11-03 | Sanford-Burnham Medical Researc Institute | Apelin receptor agonists and methods of use thereof |
| JP6949726B2 (ja) | 2015-05-15 | 2021-10-13 | ノバルティス アーゲー | Ｅｇｆｒ変異癌を治療する方法 |
| CN107849034B (zh) | 2015-06-30 | 2021-09-03 | 达纳－法伯癌症研究所公司 | Egfr抑制剂及其使用方法 |
| EP4378957A2 (en) | 2015-07-29 | 2024-06-05 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| KR102670695B1 (ko) | 2015-09-18 | 2024-06-05 | 메르크 파텐트 게엠베하 | Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도 |
| EP3350170B1 (en) | 2015-09-18 | 2022-01-26 | Merck Patent GmbH | Heteroaryl compounds as irak inhibitors and uses thereof |
| EP3858835A1 (en) * | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018112111A1 (en) * | 2016-12-13 | 2018-06-21 | Health Research, Inc. | Epidermal growth factor receptor (egfr) targeted photosensitizers |
-
2020
- 2020-06-23 CN CN202080045795.1A patent/CN114007698B/zh active Active
- 2020-06-23 EP EP20734188.4A patent/EP3986564A1/en active Pending
- 2020-06-23 JP JP2021576576A patent/JP2022538228A/ja active Pending
- 2020-06-23 US US17/621,420 patent/US20220380382A1/en active Pending
- 2020-06-23 WO PCT/EP2020/067451 patent/WO2020260252A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020260252A5 (th) | ||
| CN105163584B (zh) | 用于治疗癌症的化合物 | |
| JP4344234B2 (ja) | タキソール増強剤化合物 | |
| DK2799070T3 (en) | EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JPWO2007023778A1 (ja) | 新規抗癌併用薬 | |
| KR102382771B1 (ko) | 증식성 질환을 위한 조합 치료 | |
| JP2022512826A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| JP7027324B2 (ja) | 増殖性疾病の組み合せ療法 | |
| JP2003535890A (ja) | アクリロイルジスタマイシン誘導体並びにトポイソメラーゼｉ及びｉｉ阻害剤を含む薬剤組成物 | |
| BRPI0617730A2 (pt) | agente para prevenir ou tratar cáncer do páncreas, cáncer de ovário ou cáncer hepático contendo nova pró-fármaco hidrossolúvel | |
| US12011427B2 (en) | Methods of treating cancer | |
| AU2015355965B2 (en) | Novel PEG derivative | |
| ZA200501196B (en) | Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases | |
| JP2011225510A (ja) | 新規な抗腫瘍剤 | |
| JP2003535874A (ja) | 置換アクリロイルジスタマイシン誘導体、タキサン類及び／又は代謝拮抗剤を含む腫瘍に対する併用療法 | |
| WO2019230679A1 (ja) | 抗腫瘍剤及び腫瘍治療方法 | |
| RU2021106915A (ru) | Комбинированная терапия злокачественной опухоли с использованием производного хинолинкарбоксамида | |
| JP5794873B2 (ja) | 抗腫瘍剤 | |
| JP2011522887A (ja) | チアゾール化合物及び組成物並びにその使用方法 | |
| NZ740252B2 (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| JP2014091712A (ja) | Ｈｓｐ９０阻害剤と抗腫瘍性タキサン化合物との組み合わせ |